Melanoma MRI

Revision as of 18:45, 4 January 2019 by Sabawoon Mirwais (talk | contribs)
Jump to navigation Jump to search

Melanoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Melanoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Melanoma MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Melanoma MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Melanoma MRI

CDC on Melanoma MRI

Melanoma MRI in the news

Blogs on Melanoma MRI

Directions to Hospitals Treating Melanoma

Risk calculators and risk factors for Melanoma MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.

Overview

MRI can be useful in the staging of brain and liver metastases. Brain MRI may be considered for the diagnosis of metastatic lesions in patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma in patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years).

MRI

  • MRI can be useful in the staging of brain and liver metastases.[1][2]
  • Malignant melonoma on MRI can present as an enhancing mass with low to intermediate signal intensity and a high-signal intensity.[3]
  • MRI can also show regional lymphadenopathy in malignant melanoma.[3]
  • Brain MRI is recommended for the diagnosis of metastatic lesions in the following conditions:[4]
  • In patients who have been diagnosed with stage IA-IV melanoma
  • For secondary prevention of melanoma in patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years)

References

  1. Perng, Powell; Marcus, Charles; Subramaniam, Rathan M. (2015). "18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". American Journal of Roentgenology. 205 (2): 259–270. doi:10.2214/AJR.14.13575. ISSN 0361-803X.
  2. Nanni, C.; Fantini, L.; Nicolini, S.; Fanti, S. (2010). "Non FDG PET". Clinical Radiology. 65 (7): 536–548. doi:10.1016/j.crad.2010.03.012. ISSN 0009-9260.
  3. 3.0 3.1 Ogura I, Sasaki Y, Kameta A, Sue M, Oda T (2017). "A Rare Case of Malignant Melanoma of the Mandible: 
CT and MRI Findings". Chin J Dent Res. 20 (2): 111–114. doi:10.3290/j.cjdr.a38276. PMID 28573265.
  4. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.


Template:WikiDoc Sources